Meeting
2019 Gastrointestinal Cancers Symposium
Safety of bevacizumab in cancer patients with inflammatory bowel disease.
Authors
Ruth Gabriela Herrera Gomez
CHUV: Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Ruth Gabriela Herrera Gomez , Claire Gallois , Marcel Adler , David Malka , David Planchard , Barbara Pistilli , Michel Ducreux , Olivier Mir
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 664)
DOI
10.1200/JCO.2019.37.4_suppl.664
Abstract #
664
Poster Bd #
M9
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC).
First Author: A. Johnsson
Poster
2019 ASCO Annual Meeting
A phase II study of lenvatinib in patients with metastatic colorectal cancer refractory to standard chemotherapy: LEMON study (NCCH1503).
First Author: Hirokazu Shoji
Poster
2018 Gastrointestinal Cancers Symposium
Activity and safety of Nab-FOLFIRI and Nab-FOLFOX as first-line treatment for metastatic pancreatic cancer (phase II NabucCO study).
First Author: Elisa Giommoni
Poster
2016 Gastrointestinal Cancers Symposium
A multinational, randomized, phase III trial of XELIRI (+bevacizumab) versus FOLFIRI (+bevacizumab) as the second-line chemotherapy for metastatic colorectal cancer: Asian XELIRI project (AXEPT).
First Author: Kei Muro